

Tobacco: preventing uptake, promoting quitting and treating dependence Committee Meeting 1

Date: 04/10/24

Location: Virtual (Zoom)

Minutes: Final

Committee members present:		
Susan Harrison (Chair)	(Present for notes 1 – 5)	
Matthew Alford	(Present for notes 1 – 5)	
Prof Ian Basnett	(Present for notes 1 – 5)	
Prof Louis Levy	(Present for notes 1 – 5)	
Prof Felix Naughton	(Present for notes 1 – 5)	
Dr Elena Ratschen	(Present for notes 1 – 5)	
Dr Julian Ting	(Present for notes 1 – 5)	
Michael Wilcock	(Present for notes 1 – 5)	
Arran Woodhouse	(Present for notes 1 – 5)	

In attendance:		
Bethan Dorsett	Editor	(Present for notes 1 – 5)
Amber Hernaman	Project Manager	(Present for notes 1 – 5)
Thomas Hudson	Information Specialist	(Present for notes 1 – 5)
James Jagroo	Senior Technical Analyst	(Present for notes 1 – 5)
Alfredo Mariani	Health Economist	(Present for notes 1 – 5)
Toby Mercer	Technical Analyst	(Present for notes 1 – 5)
Clifford Middleton	Quality Consistency and Engagement Manager	(Present for notes 1 – 5)
Lesley Owen	Senior Health Economist	(Present for notes 1 – 5)
Robby Richey	Topic Lead	(Present for notes 1 – 5)
Sarah Scott	PIP Lead	(Present for notes 1 – 5)

4.0.03 DOC Cmte minutes

Apologies:		
Yvonne Hermon	Committee member	
Sally Cartwright	Committee member	

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to guideline committee meeting 1 for Tobacco.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- The clinical and cost effectiveness evidence of cytisinicline (cytisine)
- Cytisinicline recommendations

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was on the effectiveness of cytisinicline as an intervention to aid smoking cessation.

The Chair asked everyone to verbally declare any interests. No declarations were received.

3. Evidence reviews

Toby Mercer presented the clinical evidence and Alfredo Mariani presented the costeffectiveness evidence of cytisinicline.

4. Recommendations

Robby Richey led the discussions on the recommendations and James Jagroo made live edits on the day.

5. AOB

None.